Frontotemporal Dementia

Key Mechanism 1: Tau Pathology and TDP-43 Proteinopathy

Key Mechanism 2: Genetic Mutations and Familial FTD

Key Mechanism 3: Selective Vulnerability of Frontal-Temporal Networks

Key Mechanism 4: Neuroinflammation as a Secondary Pathogenic Driver

Key Mechanism 5: Astrogliosis and Glial Dysfunction

Primary FTD (Sporadic, 60% of Cases)

Genetic Forms (Familial FTD, 40% of Cases with Identified Mutations)

• C9ORF72 Expansion (25-30% of familial FTD): The most common genetic cause; GGGGCC repeat expansions (typically hundreds to thousands of repeats) impair C9ORF72 function and generate toxic dipeptide repeat proteins. Associated with younger onset (mean age 50-55 years), more aggressive course, higher frequency of ALS coexistence (30-50% of C9ORF72-FTD patients develop motor neuron disease features or frank ALS), and behavioral variant predominance. Neuroimaging shows prominent frontal atrophy.

• GRN Mutations (Progranulin, 5-10% of familial FTD): Loss-of-function mutations cause progranulin haploinsufficiency. Associated with intermediate-age onset (mean 60-65 years), slower progression than C9ORF72, high penetrance (>90%), and semantic variant language impairment (svPPA) more common than behavioral variant. Autopsy studies show TDP-43 pathology. Characterized by prominent anterior temporal lobe atrophy.

• MAPT Mutations (Microtubule-Associated Protein Tau, 5-10% of familial FTD): Cause tau pathology with classic Pick bodies. Associated with behavioral variant predominance, highly variable onset (30s-80s depending on specific mutation), and often family history clearly evident. Neuroimaging shows frontal predominance.

Other Genetic Causes (<5% of familial FTD)

• CHMP2B (chromatin-modifying protein 2B): Rare, associated with FTD-dementia with Lewy bodies variant
• VCP (valosin-containing protein): Rare, often presents with myopathy in addition to FTD
• UBIQUITIN (ubiquitin): Rare, associated with TDP-43 pathology
• Emerging genes identified through next-generation sequencing: ATXN2, UNC13A, hnRNPA1, others

Risk Factors for Sporadic FTD

• Age: Risk increases with advancing age, though FTD is distinctly a disease of younger-old (40-65 years typically)
• Male sex: Males affected more frequently than females (approximately 1.5:1 ratio), though reasons unclear
• Head trauma: Some epidemiological studies suggest prior traumatic brain injury may increase risk, though causality not firmly established
• Genetic predisposition: Familial history is the strongest risk factor; relatives of FTD patients have 50% recurrence risk (autosomal dominant) and should be offered genetic testing and counseling

Key Distinction from Alzheimer Disease Risk Factors

Behavioral Variant FTD (bvFTD, 60% of FTD Cases)

• Disinhibition and Behavioral Changes: Patients lose appropriate social restraint and demonstrate impulsive, inappropriate behavior. Manifestations include making obscene jokes or comments in social settings, engaging in inappropriate sexual behavior, shoplifting or other antisocial acts, excessive alcohol consumption, or food-seeking behavior (hyperphagia) with marked weight gain. The pathophysiological basis is degeneration of orbitofrontal cortex regions that normally inhibit automatic or socially inappropriate responses. This often leads families to describe a "change in personality" or friends noting the person "is not themselves anymore."

• Apathy and Loss of Initiative: Progressive apathy and loss of motivation are hallmark features; patients become indifferent to their appearance, hygiene, and family responsibilities. They may sit passively for hours without initiating activity. This reflects prefrontal cortex degeneration affecting motivation circuits (dorsolateral prefrontal cortex and anterior cingulate). Importantly, apathy in bvFTD differs from depression—patients lack the dysphoria and guilt of depression; they are simply unmotivated. This distinction is crucial clinically because antidepressants are ineffective, and recognizing apathy prevents misattribution to mood disorder.

• Loss of Empathy and Theory of Mind: Early and striking loss of empathy for others' emotions and reduced ability to understand others' mental states (diminished theory of mind). Patients may respond callously to others' suffering, make inappropriate comments about deceased family members, or seem indifferent to major life events. Neuroimaging shows anterior insula and temporopolar cortex involvement, structures critical for emotional processing and mentalizing.

• Stereotyped and Repetitive Behaviors: Patients develop rigid, repetitive behaviors or routines—repetitive questioning, stereotyped phrases, compulsive collecting, or adherence to precise rituals. These reflect preserved automatic/habit systems with loss of executive override.

• Cognitive Changes in bvFTD: Memory is relatively spared early (unlike Alzheimer disease), but executive function is impaired: patients show poor planning, impulsive decision-making, poor judgment, and reduced insight into their changes. This lack of awareness (anosognosia) is characteristic and may prevent patients from seeking help.

• Physical Examination in bvFTD: Neurological examination is often surprisingly normal in early stages, which helps distinguish FTD from Parkinsonian syndromes. Later, motor features may emerge (see below).

Primary Progressive Aphasia (PPA, 25% of FTD Cases)

• Semantic Variant PPA (svPPA, formerly Semantic Dementia, ~45% of PPA cases): Characterized by selective loss of semantic memory (meaning of words, facts, concepts) while phonology, grammar, and syntax remain relatively preserved initially. Patients struggle to name objects ("What do you call that?" while pointing) and cannot define words or answer factual questions, but they can repeat words they don't understand and grammar remains intact. For example, a patient might say "I can't find the word for that thing you sit on" (semantic retrieval failure) but can repeat "chair" perfectly. Comprehension is impaired proportionally to semantics. Neuroimaging shows prominent anterior temporal lobe atrophy (left > right for language; bilateral in some cases). As disease progresses, behavioral changes emerge. This variant is associated with GRN mutations and TDP-43 pathology in most cases.

• Nonfluent Variant PPA (nfvPPA, ~25% of PPA cases): Characterized by effortful, agrammatic speech (impaired grammar) with relatively preserved comprehension and semantics. Speech is slow, halting, with shortened phrases and omission of function words. A patient might say "go...store...need...milk" (agrammatism). Repetition is impaired (unlike Broca aphasia in acute stroke). Comprehension of complex grammar is impaired. Apraxia of speech (motor speech planning defect) may be prominent. Neuroimaging shows left inferior frontal cortex atrophy. Associated with tau pathology and MAPT mutations in some cases. As disease progresses, behavioral features emerge.

• Logopenic Variant PPA (lvPPA, ~20% of PPA cases): Characterized by impaired word retrieval (anomia) and impaired repetition (often of long phrases or sentences), with preserved grammar and relatively preserved single-word comprehension. Speech is slow and halting due to word-finding pauses. Repetition deficit distinguishes this from semantic variant. Neuroimaging shows left temporo-parietal atrophy (different from svPPA and nfvPPA, which show more frontal-anterior temporal changes). Important board distinction: logopenic variant is more frequently associated with Alzheimer pathology (amyloid and tau) rather than FTD pathology, though it can occur in FTD. This has important prognostic and treatment implications.

Motor Neuron Disease-FTD (FTD-MND or FTD-ALS, 5-15% of FTD Cases)

• Motor Features: Patients develop progressive weakness, fasciculations, hyperreflexia, or Babinski signs indicating motor neuron involvement. Some patients have frank ALS features (lower motor neuron signs) concurrent with upper motor neuron signs, or purely upper motor neuron signs (Primary Lateral Sclerosis, PLS, variant). C9ORF72 expansion carriers have particularly high risk of ALS coexistence (30-50% develop MND features). The motor and cognitive decline progress in parallel, though rates may differ.

• Clinical Significance: Recognition is important because FTD-MND patients often present initially to neurology with motor complaints, and the cognitive/behavioral changes may be attributed to depression or emotion following diagnosis of ALS, delaying FTD recognition. Conversely, patients presenting with behavioral FTD may be found on careful examination to have subtle motor signs.

Other Clinical Features Common Across FTD Variants

• Preserved Memory (Early): Unlike Alzheimer disease where episodic memory loss is the hallmark early feature, FTD patients often retain the ability to remember recent conversations and events (though they may not care about them due to apathy), and recognition memory is typically preserved. This is a key distinguishing feature on cognitive testing.

• **Preserved

Step 1 — Characterize the syndrome

• History from an informant: the single most valuable diagnostic maneuver, because anosognosia means the patient underreports. Ask specifically about disinhibition, apathy, loss of empathy, rituals, and dietary change.
• Bedside cognitive screening: MMSE and MoCA are often near-normal early and are not sensitive to frontal dysfunction. Add frontal/executive tasks — verbal fluency, go/no-go, Luria motor sequencing, Trail Making B — and screen for frontal release signs (grasp, snout, palmomental).
• Formal neuropsychological testing demonstrates the FTD signature: executive and social-cognitive failure with disproportionately preserved episodic memory and visuospatial function (the reverse of Alzheimer disease).

Step 2 — Apply named criteria

• Rascovsky (International bvFTD Criteria Consortium, 2011) criteria for behavioral variant FTD: possible bvFTD requires ≥3 of 6 core features — disinhibition, apathy/inertia, loss of sympathy/empathy, perseverative/stereotyped/compulsive behavior, hyperorality/dietary change, and a dysexecutive neuropsychological profile with relatively spared episodic memory and visuospatial function; probable bvFTD requires the possible criteria plus significant functional decline plus frontal and/or anterior temporal atrophy or hypometabolism on imaging; definite bvFTD requires possible/probable criteria plus histopathologic confirmation or a known pathogenic mutation.
• Gorno-Tempini (2011) consensus criteria classify primary progressive aphasia into semantic, nonfluent/agrammatic, and logopenic variants.

Step 3 — Imaging and exclusion

• MRI brain (first-line structural test): focal frontal and/or anterior temporal atrophy, classically asymmetric, with knife-edge gyri and widened Sylvian fissures. Also excludes tumor, subdural hematoma, hydrocephalus, and vascular disease.
• FDG-PET is used chiefly to differentiate FTD from Alzheimer disease when the clinical picture and MRI are equivocal: frontotemporal hypometabolism precedes visible atrophy, whereas parietotemporal/precuneus hypometabolism favors Alzheimer disease.
• Amyloid PET or CSF Aβ42, total tau, and p-tau address Alzheimer pathology: a negative amyloid study argues strongly against Alzheimer disease and thus supports FTD, while a positive result is less specific in older patients (incidental amyloid is common) and must be interpreted alongside the clinical syndrome. Alzheimer's Association–SNMMI appropriate use criteria restrict amyloid PET to persistent diagnostic uncertainty in patients with objective cognitive impairment.
• Screen reversible mimics: TSH, B12, metabolic panel, HIV and syphilis serologies when risk factors exist.
• Genetic testing (C9ORF72 repeat-primed PCR plus MAPT/GRN sequencing) with counseling when family history, early onset, or coexisting ALS is present.
• Gold standard remains autopsy: Pick bodies (argyrophilic, 3-repeat tau) or ubiquitinated TDP-43 inclusions.

Immediate priorities (safety first)

• Risk containment: assess driving fitness (per AAN guidance on driving in dementia), remove firearms, transfer financial control, and establish a durable power of attorney and advance directives while capacity is partially retained. Disinhibited spending, shoplifting, and sexual behavior create urgent medicolegal exposure.
• Caregiver education and behavioral strategy are first-line for behavior in dementia per the American Psychiatric Association's guideline on agitation/psychosis in dementia: identify triggers, redirect rather than confront, structure routines, and restrict access to food to limit hyperorality-driven weight gain.

Pharmacologic therapy (all off-label)

• SSRIs (e.g., sertraline, citalopram) are the usual first-line drug class for disinhibition, compulsions, repetitive behaviors, and hyperorality, exploiting the serotonergic deficit that characterizes FTD.
• Trazodone is a reasonable alternative or add-on for agitation and sleep disruption.
• Atypical antipsychotics (e.g., quetiapine) are reserved for dangerous agitation or psychosis refractory to the above, used at the lowest dose for the shortest duration, with documented risk–benefit discussion — the FDA boxed warning for increased mortality in elderly patients with dementia applies, and FTD patients are notably sensitive to extrapyramidal effects.
• Nonpharmacologic disease-specific therapy: speech-language pathology for PPA (communication strategies, augmentative devices), physical/occupational therapy, and dysphagia evaluation.
• In FTD-ALS, the ALS component is managed per AAN ALS practice parameters — riluzole, noninvasive ventilation guided by respiratory function, and multidisciplinary clinic care.
• Genetic counseling for the patient and at-risk first-degree relatives; refer mutation carriers to trials (e.g., antisense oligonucleotide programs).
• Palliative care and hospice referral as function declines.

What to avoid

• Cholinesterase inhibitors (donepezil): not recommended — no benefit and may worsen behavioral symptoms; the cholinergic system is relatively spared in FTD.
• Memantine: randomized data showed no benefit in FTD.
• Typical antipsychotics (haloperidol) and high-potency agents: avoid given EPS sensitivity and mortality risk.
• Benzodiazepines: avoid — disinhibition, falls, and delirium.

Disease-related — emergencies flagged

• Aspiration pneumonia (EMERGENCY): bulbar weakness in FTD-ALS plus hyperorality, rapid eating, and impaired airway protection lead to aspiration; this is the most common terminal event in dementia generally. Signals: fever, hypoxia, new focal infiltrate, coughing with meals.
• Neuromuscular respiratory failure (EMERGENCY) in FTD-ALS: diaphragmatic weakness produces orthopnea, morning headache, and a falling forced vital capacity before overt dyspnea appears — hypercapnia, not hypoxia, is the early signal.
• Choking/asphyxiation: hyperorality with cramming of non-food objects (pica) plus loss of executive restraint.
• Malnutrition or, conversely, marked weight gain: hypothalamic and orbitofrontal degeneration drives carbohydrate craving early; dysphagia drives weight loss late.
• Falls and fractures: parkinsonism in tau-associated FTD and corticobasal/PSP overlap syndromes.
• Financial exploitation, arrest, and job loss: disinhibition plus loss of empathy and anosognosia; often the presenting "complication" before diagnosis.
• Elder abuse and caregiver burnout/depression: FTD imposes higher caregiver burden than Alzheimer disease because patients are younger, physically strong, and behaviorally disruptive.
• Suicide risk in mutation carriers who learn their status and in early insight-preserved disease.
• Late-stage mutism, incontinence, and immobility with pressure ulcers and venous thromboembolism.

Treatment-related

• Antipsychotics: extrapolated FDA boxed-warning risks of death and cerebrovascular events; FTD patients show heightened parkinsonism and are at risk for neuroleptic malignant syndrome (EMERGENCY — hyperthermia, lead-pipe rigidity, elevated creatine kinase) and QT prolongation with torsades.
• SSRIs: hyponatremia/SIADH (check sodium after initiation in older adults), bleeding risk with antiplatelets, QT prolongation with citalopram, and serotonin syndrome (EMERGENCY) if combined with other serotonergic agents.
• Trazodone/benzodiazepines: orthostasis, sedation, falls, paradoxical disinhibition.
• PEG tube placement: does not prevent aspiration in advanced dementia and carries procedural and site-infection risk — a key counseling point.

• The stem's signature: a patient in the 50s–60s with new socially inappropriate behavior, apathy, loss of empathy, compulsive rituals, and hyperorality — with normal or near-normal MMSE and preserved episodic memory. Early personality change with spared memory = FTD; early memory loss = Alzheimer disease.
• Single best next step when FTD is suspected: MRI brain, looking for focal, often asymmetric frontal and/or anterior temporal atrophy (knife-edge gyri). FDG-PET showing frontotemporal hypometabolism is the follow-up when MRI is equivocal.
• The buzzword pathology: Pick bodies — round, silver-staining (argyrophilic) intraneuronal inclusions of hyperphosphorylated 3-repeat tau. But remember only a minority of FTD is Pick disease; TDP-43 inclusions are at least as common, and autopsy remains the gold standard.
• The association examiners love: C9ORF72 hexanucleotide (GGGGCC) repeat expansion — the most common genetic cause of FTD and of familial ALS. Any stem pairing behavioral change with fasciculations, hyperreflexia, or a Babinski sign is pointing at FTD-ALS.
• Language variants: fluent speech with anomia and loss of word meaning but intact repetition = semantic variant (anterior temporal atrophy); effortful agrammatic speech with apraxia of speech = nonfluent variant (left inferior frontal). Impaired repetition of long phrases = logopenic variant, which most often reflects Alzheimer pathology — a favorite trap.
• Common distractor — donepezil: cholinesterase inhibitors are not indicated in FTD and may worsen behavior; memantine has shown no benefit. Behavioral symptoms are managed with caregiver-directed nonpharmacologic strategies first, then an SSRI.
• Second distractor — primary psychiatric disease: bvFTD is routinely misdiagnosed as late-onset bipolar disorder, depression, or midlife crisis. The discriminator is apathy without dysphoria or guilt, plus anosognosia.
• Antipsychotics carry an FDA boxed warning for increased mortality in dementia; FTD patients are especially prone to extrapyramidal effects — reserve for dangerous agitation, per APA guidance.